Gene duplication and subsequent evolutionary divergence have allowed conserved proteins 32 to develop unique roles. The MarR family of transcription factors (TFs) has undergone extensive 33 duplication and diversification in bacteria, where they act as environmentally-responsive 34 repressors of genes encoding efflux pumps that confer resistance to xenobiotics, including many 35 antimicrobial agents. We have performed structural, functional, and genetic analyses of 36 representative members of the SlyA/RovA lineage of MarR TFs, which retain their ancestral 37 functions, including repression of their own expression and that of divergently-transcribed multi-38 drug efflux pumps, as well as allosteric inhibition by aromatic carboxylate compounds. In contrast 39 to other MarR family members, SlyA and RovA have acquired the ability to counter-silence 40 horizontally-acquired genes, which has greatly facilitated the evolution of Enterobacteriaceae by 41 horizontal gene transfer. SlyA/RovA TFs in different species have independently evolved novel 42 regulatory circuits to provide the enhanced levels of expression required for their new role. This 43 demonstrates the ability of TFs to acquire new functions as a result of evolutionary divergence of 44 cis-regulatory sequences.
Introduction 46 As organisms adapt to new or changing environments, their regulatory networks must 47 5 lineage to identify the evolutionary changes that allowed SlyA to adopt its new role. Here we show 91 that SlyA has retained the ability to undergo conformational changes in response to aromatic 92 carboxylates, regulate gene expression in an environmentally-responsive manner, and repress the 93 expression of a linked drug efflux system. We further show that SlyA/RovA promoters have 94 evolved to support the higher levels of expression that are required for counter-silencing. Finally, 95 we show that linked efflux pumps are not conserved in some Enterobacteriaceae, even though 96 SlyA/RovA TFs have been evolutionarily retained, suggesting that these regulators have been 97 conserved not due to their primordial role in regulating antimicrobial resistance but rather as a 98 consequence of their counter-silencing function, which is essential to maintain the regulated 99 expression of horizontally-acquired genes in Enterobacteriaceae.
7
[2] varying rates of exchange of amide protons with solvent, or [3] conformational exchange. 137 Previous studies of MarR found that apo-MarR is also highly disordered (14), suggesting that the 138 observed spectral characteristics of apo-SlyA can be ascribed to the presence of multiple 139 conformational states in solution. Addition of salicylate to SlyA induces chemical shift 140 perturbations throughout the spectrum and nearly 90% of expected resonances are now observed. 141 The large-scale changes in chemical shifts show that backbone amides throughout the protein are 142 stabilized in a different environment relative to apo-SlyA. These observations are consistent with 143 ligand binding to SlyA dimers inducing global structural changes, likely stabilizing a single protein 144 conformation in solution, a conformation that is no longer able to interact with specific high- 145 affinity DNA binding sites.
147
Crystal structure of salicylate-SlyA. To further analyze the mechanism of allosteric inhibition 148 of SlyA, the structure of the salicylate-SlyA co-crystal was determined. Studies by other groups 149 have previously determined the structure of apo-SlyA and the SlyA bound to DNA (32), 150 demonstrating that SlyA is similar in overall structure to other MarR proteins, consisting of six 151 alpha helices ( Fig. 3 ). Helices α1, α5, and α6 make up the dimerization domain, while α3 and α4, 152 along with the wing region between α4 and α5 comprise the wHTH DNA-binding domain. These with a high-affinity binding site, the helices move a significant distance to accommodate the 32Å 156 distance between major grooves.
157
SlyA formed large crystals in the presence of 75mM sodium salicylate ( Fig. S4 ). However, 158 we were unable to obtain usable crystals of apo-SlyA. Diffraction data set and refinement statistics 8 are summarized in Tables S1 and S2, respectively. The two SlyA molecules in the asymmetric unit 160 form two different SlyA dimers in this crystal form. Space group symmetry operations generate 161 the other subunit in each dimer. The dimers are very similar in structure, and further discussion 162 will focus on the dimer formed by polypeptide chain A. We were unable to observe electron 163 density for the tips of the wings, so these regions are absent from our structural model. Difference Table S3 ). Cluster I exhibited complete conservation of the salicylate-binding residues. Cluster II the effect reaching saturation at a 500 nM concentration (Fig. 5B ). RovA has also retained the 250 ability to respond to salicylate ( Fig. 5C ), despite the presence of an H38Y mutation in the second 12 salicylate-binding pocket (Table S3) (Fig. 6C ), suggesting that PslyAEco is less 295 responsive to environmental signals associated with virulence gene expression in Salmonella, 296 and thus is unable to regulate slyA expression in a manner appropriate for counter-silencing.
14 Parallel experiments in Y. pseudotuberculosis revealed that rovA is also more strongly expressed 298 from its native promoter (ProvAYps) than from a chimera expressing rovA from PslyAEco ( acquiring an ability to act as pleiotropic counter-silencers of horizontally-acquired genes. The 307 latter role has been facilitated by the parallel evolution of cis-regulatory elements that support 308 higher levels of gene expression. 309 SlyA, like other MarR family TFs, is subject to allosteric inhibition by small aromatic 310 carboxylate compounds such as salicylate, which bind and stabilize the SlyA dimer in a 311 conformation unfavorable for DNA binding (Fig. 2, Fig. S3 ). However, the specific structure and 312 arrangement of the effector binding sites varies significantly among the MarR family. Our 313 structural data indicate that SlyA binds a total of six salicylate molecules per dimer, although two 314 of these are not likely to be biologically relevant (Fig. 3) . Although the general structure and SlyA, cysteine oxidation, which has also been described in the MarR family TF OhrR (45), may 332 be a common inhibitory mechanism. Indeed, SlyA contains a cysteine residue that is conserved 333 throughout the Enterobacteriaceae at position 82 (Fig. S5 ).
334
A phylogenetic analysis of SlyA orthologs in Enterobacteriaceae demonstrates that the 335 SlyA lineage is strongly conserved, even in endosymbiotic species exhibiting significant genome 336 loss (Fig. 4, Fig. S5 ). This suggests that SlyA has a central and essential role in the transcriptional 337 regulatory networks of these species. For example, a recent analysis of the endosymbiont W. 338 glossinidia found that slyA is subject to significant evolutionary constraints (46). This conservation 339 does not appear to be due to its role as a regulator of antimicrobial resistance, as slyA does not role in E. coli, despite exhibiting a much higher degree of similarity to slyASTM than does rovA. 352 These differing roles are attributable to differences in expression, as SlyAEco is able to function as 353 a counter-silencer in S. Typhimurium when its expression is driven by the S. Typhimurium 354 promoter (Fig. 6) . We also observed that slyAEco transcription is significantly reduced in medium the rovA promoter of Y. pseudotuberculosis drives rovA transcription more strongly than PslyAEco 362 in a chimeric strain (Fig. S7 ). We conclude that the ability of a given SlyA ortholog to serve as a 
Materials and methods.

390
Bacterial strains and general reagents. All oligonucleotides and plasmids used in this study are 391 described in Table S4 and Table S5 , respectively. Unless otherwise indicated, bacteria were grown 
475
The crystal was frozen at 100°K in its crystallization solution for diffraction data 476 collection on GM/CA-CAT beamline 23-ID-D at the Advanced Photon Source. The space group 477 for the crystals is P21212 with two SlyA molecules in the asymmetric unit. The diffraction data 478 were processed with HKL2000 (62). Dataset statistics are shown in Table S1 . The crystal structure 479 of the salicylate complex of SlyA was solved using a model of a previously investigated structure 22 of apo-SlyA (unpublished data). That apo-structure was solved using the molecular replacement 481 program, MOLREP (63) with a search model generated by applying Swiss-Model (64) and the 482 SlyA amino acid sequence to PDB entry 2FBH (65). The structural model for the salicylate 483 complex was refined using REFMAC-5 (66) in the CCP4 suite (67). Rfree (68) was calculated 484 using 5% of the data in the test set. A high-resolution limit of 2.3Å was applied for the refinement, 485 consistent with standards appropriate when the structure was solved. This is the resolution at 486 which Rmerge for the data set drops below 0.40. XtalView (69) and Coot (70) were used to 487 examine sigma A weighted |Fo|-|Fc| and 2|Fo|-|Fc| electron density maps (71). MOLSCRIPT(72), 488 and Raster3D (73) were used to produce structural figures for this paper. Table S2 contains 489 refinement statistics for the structure. Coordinates and structure factors have been deposited in the 490 Protein Data Bank with identifier 3DEU. 491 492 6×His-RovA purification. RovA was purified using the same protocol as described previously 493 for SlyA (16). However, overexpression cultures were grown at 24°C to OD600=0.5. IPTG was 494 added to a final concentration of 1mM, and cultures were incubated at 24°C for an additional four 495 h before the cells were harvested by centrifugation and cell pellets stored at -80°C for the 496 subsequent purification of RovA.
498
In vitro transcription. IVT assays were performed essentially as previously described (16) with 499 the following modifications. All SlyA IVT assays were performed at 37°C. All RovA IVT assays 500 were performed at 24°C. Where indicated, sodium salicylate was added to IVT reactions prior to 501 the addition of SlyA or RovA. All oligonucleotides and templates used in IVT reactions are 502 indicated in Table S6 . 
